7.1. minimal recommendations follow-up. based different risks relapse depending diagnosis initial treatment, three major follow-up groups defined: patients seminoma stage i;patients non-seminoma stage active surveillance;all patients received either adjuvant treatment curative chemotherapy good- intermediate-prognosis metastatic disease (according igcccg) achieving complete remission with, without, surgery (for seminoma includes residual lesions < 3 cm, residual lesions > 3 cm fdg-pet-negative). important note patients achieving complete remission presenting poor-prognosis disease followed individually specialised centres. tables 10-12 show minimal recommendations follow-up three different groups based recommendations developed european society medical oncology (esmo) consensus conference . mri ct used evaluate retroperitoneum, pelvis inguinal regions sites metastatic disease gct . magnetic resonance imaging benefits absence ionising radiation time consuming less readily available ct . given frequency follow-up, number years studies estimated risk 1 300 second malignancy related ct imaging follow-up alone , although recent dose saving protocols limitations field view mitigated somewhat. nevertheless, risk could excluded use mri follow-up. mri ct rely predominantly size cut-offs evaluation given excellent spatial resolution modalities, morphological assessment features necrosis irregular shape adjunct. sensitivity specificity vary according size cut-off used . however, studies shown comparable excellent results mri ct 98% sensitivity mri detection retroperitoneal nodal metastases gct . has, however, demonstrated reader experience important interpreting images . setting gct, one study demonstrated decreased sensitivity detection retroperitoneal nodal disease mri reported trainee radiologist sensitivity detection 80% . however, experienced radiologists study achieved sensitivity detection nodal disease 97% good interobserver agreement. therefore suggested mri used instead ct follow-up done centres/units oncological radiologists routinely report mri ct patients gct rather general radiologists may occasionally see imaging. consequently, mri abdomen used alternative cect experienced centres . diagnostic accuracy fdg-pet-ct best described therefore recommended seminoma patients post-chemotherapy residual masses > 3 cm largest diameter outlined section 6.3.2.1. performed least 2 months completion chemotherapy earlier scans may misleading due inflammation. changes related tumour necrosis. use fdg-pet-ct currently recommended surveillance. retrospective analyses indicated high diagnostic accuracy staging follow-up patients cs 1 surveillance determining stage advanced disease . however, minimise radiation exposure considering supporting data use mri , panel currently recommend use fdg-pet-ct surveillance. serum tumour markers least invasive accessible follow-up investigations. established serum tumour markers, afp, β-hcg, ldh, may yield false positive results, levels correlated imaging findings repeated serial measurements . serum tumour markers detect microscopic disease yet visible cross-sectional imaging small proportion patients, therefore, measured recommended prescribed intervals . mir-371a-3p high diagnostic accuracy detecting histologies gct except teratoma potential detect disease recurrence earlier afp, β-hcg, ldh, cross-sectional imaging . however, promising test recommended routine practice, validated assay cut-off definitions prospective cohorts required mitigate risk false positive findings, unnecessary restaging, anxiety, over-treatment. regarding use us examination contralateral testis, majority consensus meeting participants support repeat us investigation, either negative biopsy contralateral biopsy performed . late relapse (vlr) five years rare event occurring approximately 0.5% patients based population-based analysis . aim follow-up beyond five years therefore shifts detection late side effects treatment imaging tests routinely recommended. patients vlr diagnosed due symptoms, although 50% elevated tumour markers present nsgcts . patient education regarding relapse symptoms clinician awareness important elements survivorship management. early use imaging tumour markers suspicion relapse encouraged. table 10: recommended minimal follow-up seminoma clinical stage active surveillance adjuvant treatment (carboplatin radiotherapy) modalityyear 1year 2year 3years 4 & 5after 5 yearstumour markers± doctor visit2 times2 times2 timesoncefurther management according survivorship care planchest x-ray----abdominopelvic magnetic resonance imaging (mri)/computed tomography (ct)2 times2 timesonce 36 monthsonce 60 months table 11: recommended minimal follow-up non-seminoma clinical stage active surveillance modalityyear 1year 2year 3year 4 & 5after 5 yearstumour markers± doctor visit4 times*4 times2 times1-2 timesfurther management according survivorship care planchest x-ray2 times2 timesonce, case lvi+at 60 months lvi+abdominopelvic magnetic resonance imaging (mri)/computed tomography (ct)2 timesat 24 months**once 36 months***once 60 months*** * case high-risk (lvi+) minority consensus group members recommended six times.** case high-risk (lvi+) majority consensus group members recommended additional ct eighteen months.*** recommended 50% consensus group members.lvi+ = lymphovascular invasion present table 12: recommended minimal follow-up adjuvant treatment complete remission advanced disease (excluded: poor-prognosis remission) modalityyear 1year 2year 3year 4 & 5after 5 yearstumour markers ± doctor visit4 times4 times2 times2 timesfurther management according survivorship care plan**chest x-ray1-2 timesonceonceonceabdominopelvic magnetic resonance imaging (mri)/computed tomography (ct)1-2 timesat 24 monthsonce 36 monthsonce 60 monthsthorax ct1-2 times*at 24 months*once 60 months*once 60 months* * conjunction abdominopelvic mri/ct case pulmonary metastases diagnosis.** case teratoma resected residual disease: patient remain uro-oncologist.